Syndesi Therapeutics

Syndesi Therapeutics is a clinical-stage biotechnology company pioneering the development of novel therapies that modulate synaptic function to alleviate symptoms of cognitive impairment. Syndesi's unique molecules act presynaptically by positively modulating the function of synaptic vesicle protein 2A (SV2A) to enhance synaptic efficiency, with SV2A playing a central role in regulating neurotransmission.Syndesi was co-founded by UCB Biopharma SRL and a consortium of Belgian and international investors to further develop novel SV2A modulators initially discovered by UCB.